Literature DB >> 27272449

High incidence of severe chronic GvHD after HSCT with sibling donors. A single center analysis.

M Remberger1,2, G Afram3, M Sundin4, M Uhlin1,2, K LeBlanc3, A Björklund3, J Mattsson1,2, P Ljungman1,3.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27272449     DOI： 10.1038/bmt.2016.159

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  23 in total

1.  Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.

Authors:  Andrea Bacigalupo; Teresa Lamparelli; Giovanni Barisione; Paolo Bruzzi; Stefano Guidi; Paolo Emilio Alessandrino; Paolo di Bartolomeo; Rosi Oneto; Barbara Bruno; Nicoletta Sacchi; Maria Teresa van Lint; Alberto Bosi
Journal:  Biol Blood Marrow Transplant       Date:  2006-05       Impact factor: 5.742

2.  Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle.

Authors:  D Blaise; M Kuentz; C Fortanier; J H Bourhis; N Milpied; L Sutton; J P Jouet; M Attal; P Bordigoni; J Y Cahn; J M Boiron; M P Schuller; J P Moatti; M Michallet
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

3.  Effect of Total Nucleated and CD34(+) Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Mats Remberger; Johan Törlén; Olle Ringdén; Mats Engström; Emma Watz; Michael Uhlin; Jonas Mattsson
Journal:  Biol Blood Marrow Transplant       Date:  2015-02-04       Impact factor: 5.742

4.  Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire.

Authors:  M Mohty; M Labopin; M L Balère; G Socié; N Milpied; R Tabrizi; N Ifrah; Y Hicheri; N Dhedin; M Michallet; A Buzyn; J-Y Cahn; J-H Bourhis; D Blaise; C Raffoux; H Espérou; I Yakoub-Agha
Journal:  Leukemia       Date:  2010-09-30       Impact factor: 11.528

5.  H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease.

Authors:  Bita Sahaf; Yang Yang; Sally Arai; Leonard A Herzenberg; Leonore A Herzenberg; David B Miklos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

6.  Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation.

Authors:  Mats Remberger; Britt-Marie Svahn; Jonas Mattsson; Olle Ringdén
Journal:  Transplantation       Date:  2004-07-15       Impact factor: 4.939

7.  Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.

Authors:  Nicolaus Kröger; Carlos Solano; Christine Wolschke; Giuseppe Bandini; Francesca Patriarca; Massimo Pini; Arnon Nagler; Carmine Selleri; Antonio Risitano; Giuseppe Messina; Wolfgang Bethge; Jaime Pérez de Oteiza; Rafael Duarte; Angelo Michele Carella; Michele Cimminiello; Stefano Guidi; Jürgen Finke; Nicola Mordini; Christelle Ferra; Jorge Sierra; Domenico Russo; Mario Petrini; Giuseppe Milone; Fabio Benedetti; Marion Heinzelmann; Domenico Pastore; Manuel Jurado; Elisabetta Terruzzi; Franco Narni; Andreas Völp; Francis Ayuk; Tapani Ruutu; Francesca Bonifazi
Journal:  N Engl J Med       Date:  2016-01-07       Impact factor: 91.245

8.  Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.

Authors:  Stephanie J Lee; John P Klein; A John Barrett; Olle Ringden; Joseph H Antin; Jean-Yves Cahn; Matthew H Carabasi; Robert Peter Gale; Sergio Giralt; Gregory A Hale; Osman Ilhan; Philip L McCarthy; Gerard Socie; Leo F Verdonck; Daniel J Weisdorf; Mary M Horowitz
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

9.  Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation.

Authors:  N Schmitz; A Bacigalupo; D Hasenclever; A Nagler; E Gluckman; P Clark; P Bourquelot; H Greinix; N Frickhofen; O Ringdén; A Zander; J F Apperley; C Gorin; K Borkett; G Schwab; M Goebel; N H Russell; A Gratwohl
Journal:  Bone Marrow Transplant       Date:  1998-05       Impact factor: 5.483

10.  Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations.

Authors:  O Blennow; P Ljungman; E Sparrelid; J Mattsson; M Remberger
Journal:  Transpl Infect Dis       Date:  2013-12-30       Impact factor: 2.228
View more
  3 in total

1.  Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease.

Authors:  Frida Schain; Nurgul Batyrbekova; Johan Liwing; Simona Baculea; Thomas Webb; Mats Remberger; Jonas Mattsson
Journal:  Eur J Health Econ       Date:  2020-12-04

2.  Management of Chronic Graft-vs.-Host Disease in Children and Adolescents With ALL: Present Status and Model for a Personalised Management Plan.

Authors:  Agnieszka Sobkowiak-Sobierajska; Caroline Lindemans; Tomas Sykora; Jacek Wachowiak; Jean-Hugues Dalle; Halvard Bonig; Andrew Gennery; Anita Lawitschka
Journal:  Front Pediatr       Date:  2022-02-18       Impact factor: 3.418

3.  Human placental mesenchymal stromal cell-derived exosome-enriched extracellular vesicles for chronic cutaneous graft-versus-host disease: A case report.

Authors:  Amir Hossein Norooznezhad; Reza Yarani; Mehrdad Payandeh; Zohreh Hoseinkhani; Sarah Kiani; Elham Taghizadeh; Avnesh S Thakor; Kamran Mansouri
Journal:  J Cell Mol Med       Date:  2021-12-06       Impact factor: 5.310
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.